DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty.

Author(s): O'Keefe JH Jr, Stone GW, McCallister BD Jr, Maddex C, Ligon R, Kacich RL, Kahn J, Cavero PG, Hartzler GO, McCallister BD

Affiliation(s): Mid America Heart Institute, St. Luke's Hospital, Kansas City, Missouri, USA.

Publication date & source: 1996-03-15, Am J Cardiol., 77(8):649-52.

Publication type: Clinical Trial; Randomized Controlled Trial

Combination lovastatin and probucol reduced total cholesterol (27%) and low-density lipoprotein levels (30%), but did not prevent restenosis or clinical events during the first 6 months after percutaneous transluminal coronary angioplasty.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017